Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 09, 2026, titled "Glenmark Pharmaceuticals Receives U.S. FDA Approval for Progesterone Vaginal Inserts, 100 mg".
Glenmark Pharmaceuticals Limited Press Release Apr 09 2026
Filed with NSE · · 3 pages · English
Watch Glenmark Pharmaceuticals' latest callGlenmark Pharmaceuticals (NSE:GLENMARK) Q1 2026 Earnings Call · Replay · Aug 3Read the transcript of Glenmark Pharmaceuticals (NSE:GLENMARK) Q1 2026 Earnings CallRelease
Glenmark Pharmaceuticals Limited on 6ix
Earlier from Glenmark Pharmaceuticals
- Press Release Apr 01 2026
- Glenmark Pharmaceuticals Announces Strategic Shift to Direct Commercialization and Distribution of RYALTRIS® in the U.S., Significantly Expanding Its Innovative Portfolio
- Press Release Mar 21 2026
- Press Release Mar 19 2026
- Press Release Mar 16 2026
Later from Glenmark Pharmaceuticals
- Press Release May 18 2026
- Press Release May 20 2026
- Press Release May 29 2026
- Press Release Jun 05 2026
- Glenmark Pharmaceuticals Limited Press Release Jun 11 2026
Follow Glenmark Pharmaceuticals into a list and get an email when it puts out news.
Follow Glenmark Pharmaceuticals